Prime Medicine (PRME) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Prime Medicine (PRME) right now is Narrowed focus on a liver franchise: In 2025 the company restructured around in vivo liver targets, prioritizing PM577 for Wilson Disease and PM647 for Alpha-1 Antitrypsin Deficiency (AATD). Product revenue is None (pre-revenue; collaboration income only). If that keeps playing out, the setup is favourable; the risk to it is prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. No one can predict where PRME trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Prime Medicine (PRME) higher?
Narrowed focus on a liver franchise
In 2025 the company restructured around in vivo liver targets, prioritizing PM577 for Wilson Disease and PM647 for Alpha-1 Antitrypsin Deficiency (AATD). As of Q1 2026, management guided to an IND/CTA filing for PM577 in the first half of 2026 and for PM647 around mid-2026, with initial clinical data from both expected in 2027.
Lead asset and FDA engagement
PM359, the company's program in Chronic Granulomatous Disease (CGD), generated early proof-of-concept data in patients, and Prime Medicine said it has been engaging the FDA about a potential path toward a Biologics License Application. The CGD effort was deprioritized as part of the liver pivot, but the early human data is cited as platform validation.
Bristol Myers Squibb collaboration
Prime Medicine has a research collaboration and license agreement with Bristol Myers Squibb to develop prime edited ex vivo T-cell therapies. The deal included an upfront payment of roughly ~$110 million and the potential for more than ~$3.5 billion in milestone payments over time, providing non-dilutive funding and external validation of the platform.
Platform breadth beyond current programs
The prime editing platform is designed to correct a large share of known disease-causing mutations, which the company frames as optionality across many indications. That breadth is a long-term thrust, but turning platform potential into approved products requires years of clinical work and substantial additional capital.
What could weigh on PRME?
Prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. As of March 31, 2026 the company reported roughly ~$149.2 million in cash, cash equivalents, investments, and restricted cash, which management expected to fund operations into 2027, implying that another financing will likely be needed and could dilute existing shareholders. Lead programs are still preclinical or just entering the clinic, so a failed readout, a delayed filing, or a safety setback could materially reduce the company's value. It also competes with better-capitalized gene-editing peers, some of which already have approved or later-stage products.
How to think about a PRME forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the PRME guide and whether PRME is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the PRME outlook
The bottom line: what is driving Prime Medicine (PRME) is Narrowed focus on a liver franchise, with product revenue at None (pre-revenue; collaboration income only). If that keeps playing out the setup is favourable; the risk is prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. No one can predict the price, so treat any PRME forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around PRME with Walnut
Use Prime Medicine as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Prime Medicine (PRME)?
+
No one can reliably predict where PRME will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Prime Medicine higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive PRME higher?
+
The main growth drivers are Narrowed focus on a liver franchise; Lead asset and FDA engagement; Bristol Myers Squibb collaboration. Whether they play out is the real question, not a guaranteed path.
What are the risks to PRME?
+
Prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. As of March 31, 2026 the company reported roughly ~$149.2 million in cash, cash equivalents, investments, and restricted cash, which management expected to fund operations into 2027, implying that another financing will likely be needed and could dilute existing shareholders. Lead programs are still preclinical or just entering the clinic, so a failed readout, a delayed filing, or a safety setback could materially reduce the company's value. It also competes with better-capitalized gene-editing peers, some of which already have approved or later-stage products.
Will PRME stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Prime Medicine's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is PRME a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the PRME "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.